How effective is Lucentis for Macular Degeneration? (a real world drug study)
Summary:
Overall ratings: 3.7/5 Long term ratings: 3.8/5
This is a phase IV clinical study of how effective Lucentis (ranibizumab) is for Macular degeneration and for what kind of people. The study is created by eHealthMe from 19 Lucentis users and is updated continuously.
What is Lucentis?
Lucentis has active ingredients of ranibizumab. It is often used in macular degeneration. eHealthMe is studying from 25,647 Lucentis users. Check the latest studies of Lucentis.
What is Macular degeneration?
Macular degeneration (painless eye condition that leads to the gradual loss of central vision) is found to be associated with 861 drugs and 1,489 conditions by eHealthMe. Check the latest studies of Macular degeneration.
eHealthMe: drug outcomes in the real world
eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.
19 people are studied for taking Lucentis in Macular degeneration
Overall effectiveness (number of people):
Long term (1+ years) effectiveness (number of people):
Lucentis effectiveness for Macular degeneration (number of people):
Overall:
- not at all: 1
- somewhat: 1
- moderate: 5
- high: 8
- very high: 4
Long Term:
- not at all: 1
- somewhat: 0
- moderate: 2
- high: 5
- very high: 3
Gender of people who take Lucentis for Macular degeneration *:
- female: 68.42 %
- male: 31.58 %
Age of people who take Lucentis for Macular degeneration *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 5.26 %
- 40-49: 0.0 %
- 50-59: 15.79 %
- 60+: 78.95 %
Who find Lucentis more effective for Macular Degeneration?
Gender of people who take Lucentis for Macular degeneration *:
- female: 66.67 %
- male: 33.33 %
Age of people who take Lucentis for Macular degeneration *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 0.0 %
- 40-49: 0.0 %
- 50-59: 16.67 %
- 60+: 83.33 %
* Approximation only. Some reports may have incomplete information.
Do you take Lucentis?
- You can start a phase IV clinical trial to monitor Lucentis safety and effectiveness.How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Related studies
Alternative drugs to, pros and cons of:
- Lucentis (25,647 reports)
Treatments, associated drugs and conditions:
- Macular degeneration (25,572 reports)
How the study uses the data?
The study is based on ranibizumab (the active ingredients of Lucentis) and Lucentis (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study neither.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Pain and Tooth Extraction - a second ago
- Could Erythromycin Estolate cause Red Blood Cell Sedimentation Rate Increased? - a second ago
- Could Avelox cause Diarrhea Aggravated? - 3 seconds ago
- Magnesium and Limb Injury for Men aged 50-59 - 4 seconds ago
- Platelet Count Increased and drugs of ingredients of venlafaxine hydrochloride - 7 seconds ago
- Cymbalta and Speech Impairment (Adult) for Men aged 60+ - 8 seconds ago
- Cymbalta and Slurred Speech for Men aged 60+ - 8 seconds ago
- Cymbalta and Language Impairment for Men aged 60+ - 9 seconds ago
- Cymbalta and Inability To Speak for Men aged 60+ - 9 seconds ago
- Cymbalta and Impairment Of Speech for Men aged 60+ - 9 seconds ago